North American Biologicals, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Announces a public offering of 4.2 mil. shares of common stock. The Miami, Florida-based provider of human blood plasma elements and plasma/sera-based diagnostic products will offer 2.7 mil. shares, and two selling shareholders will offer 1.5 mil. Assuming the company's planned selling price of $6.50 per share, NABI will gain net proceeds of approximately $15.5 mil. through its 2.7 mil. shares. Additional proceeds could be realized through the sale of 630,000 over-allotment shares by underwriters Raymond James-& Associates and NatWest Securities Limited.